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Systemic fungal infections remain a significant cause of mortality in neutropenic
and immunocompromised patients, despite advances in their diagnosis and
treatment. The incidence of such infections is rising due to the use of intensive
chemotherapy regimens in patients with solid tumours or haematological cancers,
the increasing numbers of allogeneic haematopoietic stem cell and solid organ
transplants, and the use of potent immunosuppressive therapy in patients with
autoimmune disorders. In addition, the epidemiology of systemic fungal infections
is changing, with atypical species such as Aspergillus terreus and zygomycetes
becoming more common. Treatment has traditionally focused on empirical
therapy, but targeted pre-emptive therapy in high-risk patients and prophylactic
antifungal treatment are increasingly being adopted. New treatments, including
lipid formulations of amphotericin B, second-generation broad-spectrum azoles,
and echinocandins, offer effective antifungal activity with improved tolerability
compared with older agents; the potential impact of these treatments is reflected in
their inclusion in current treatment and prophylaxis guidelines. New treatment
strategies, such as aerosolized lipid formulations of amphotericin B, may also
reduce the burden of mortality associated with systemic fungal infections. The
challenge is to identify ways of coupling potentially effective treatments with early
and reliable identification of patients at highest risk of infection.
Keywords amphotericin B, azoles, echinocandins, transplantation, neutropenia,
aspergillosis, zygomycosis
Introduction
The incidence of systemic fungal infections such as
invasive aspergillosis (IA) has increased during the
past two decades, largely due to the use of intensive
chemotherapy regimens in patients with haematological
malignancies, increasing numbers of allogeneic haema-
topoietic stem cell and solid organ transplants, and the
broad use of potent immunosuppressive therapy in
many different patient groups [1]. This increase has
been facilitated by improvements in the management of
such infections resulting from the introduction of more
effective drugs, and the advent of new diagnostic
approaches, such as high-resolution computed tomo-
graphy (CT) [2] and Aspergillus galactomannan antigen
assays [3], that may provide early identification and
treatment. Despite these advances, however, mortality
and morbidity remain high. For example, in a meta-
analysis of 50 trials including a total of 1941 patients,
the overall case-fatality rate associated with IA was
58%, and mortality rates ranged from 49.3% in patients
Correspondence: Georg Maschmeyer, Professor of Internal Medicine,
Chief, Department of Haematology and Oncology, Director, Center
for Haematology, Oncology and Radiotherapy, Klinikum Ernst von
Bergmann, Charlottenstrasse 72, D-14467 Potsdam, Germany. Tel:
49 331 241 6001; fax: 49 331 241 6000; E-mail:
gmaschmeyer@klinikumevb.de
Rece ived 28 November 2008 ; Fina l rev i s ion rece ived
30 March 2009; Accepted 3 April 2009
– 2009 ISHAM DOI: 10.1080/13693780902946559
Medical Mycology September 2009, 47, 571583
with leukaemia or lymphoma to 86.7% in patients
undergoing allogeneic bone marrow transplantation
[4]. In contrast, starting effective systemic antifungal
therapy (AFT) pre-emptively, based upon early diag-
nosis of pulmonary infiltrates by means of serial
thoracic CT scans, may reduce aspergillosis-related
mortality to below 20% [5]. However, the cultural or
histological proof of invasive mould infection (IMI) is
lacking in almost all of these patients, so that an
undefined number of patients may also have had
non-fungal causes of their pulmonary infiltrates.
The importance of prompt and effective treatment
of systemic fungal infections is highlighted by a study
that compared primary treatment with voriconazole
versus intravenous amphotericin B, both followed by
oral licensed AFT, in patients with IA, the majority of
whom had haematological disorders [6]. The overall
response rate (both complete and partial responses)
was 52.8% with voriconazole and 31.6% with ampho-
tericin B, and the survival rates at 12 weeks were
70.8% and 57.9%, respectively (hazard ratio [HR] 0.59,
95% confidence interval [CI] 0.400.88, P0.02).
Importantly, the study showed that unsuccessful first-
line therapy can markedly affect the response to
subsequent treatment: among patients who were
switched to other antifungal agents because of insuffi-
cient clinical response, only 26% of those originally
randomized to voriconazole, and 19% of those rando-
mized to amphotericin B, showed a successful outcome
at 12 weeks [7].
Some important aspects of the epidemiology and
current management of invasive fungal infections are
updated in this paper.
Epidemiology and risk factors of invasive
fungal infections
Although Aspergillus and Candida species remain the
principal pathogens associated with invasive fungal
infections, the epidemiology of such infections has
changed considerably during the past three decades,
and is continuing to evolve. Prior to the 1980s, the
majority of deaths from systemic fungal infections were
associated with Candida species, but following the
introduction of fluconazole, Candida-related deaths
have decreased while infections caused by moulds,
particularly Aspergillus species, have increased [8,9];
indeed, Aspergillus is now the most common cause of
systemic fungal infections in patients undergoing
allogeneic bone marrow transplantation and those
with acute leukaemia undergoing intensive chemother-
apy [10]. Patients with haematological malignancies
account for approximately 5060% of systemic fungal
infections (Fig. 1) [11]. Moreover, the incidence
of fungal infections in these patients is increasing
(Fig. 2) [1214] and retrospective autopsy data show
that approximately 75% of such infections are not
diagnosed prior to death [13].
Among 395 patients undergoing allogeneic haema-
topoietic stem cell transplantation, 2-year survival
among those with a non-Candida systemic fungal
infection was 20%, compared with 55% among non-
infected patients (PB0.0001); the development of a
non-Candida infection was the strongest independent
risk factor for death, with an odds ratio of 5.6 (95%
CI 3.78.6, PB0.0001) [15]. The principal risk factors
for the development of such infections in these patients
Fig. 1 Underlying diseases in 88 patients with invasive aspergillosis
[11].
Fig. 2 Incidence of mould and yeast infections in patients with
haematological malignancies between 1999 and 2003 [12].
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were moderate-to-severe graft-versus-host disease
(GVHD; odds ratio [OR] 4.6, 95% CI 2.29.7,
PB0.0001) and corticosteroid treatment for GVHD
(OR 2.1, 95% CI 1.14.1, P0.04). The risk of
infection increased from 411% when one of these
risk factors was present, and to 33% when both were
present [15]. Cytomegalovirus (CMV) infection is also
a significant risk factor for IA in patients undergoing
allogeneic stem cell transplants; in a study in 1682
patients, those infected with this virus were seven times
(95% CI 4.510.8) more likely to develop IA than those
without CMV [14]. The susceptibility of patients
with CMV disease to opportunistic fungal infections
reflects the known immunosuppressant effects of CMV
[1618], particularly against cell-mediated immune
responses, and is probably also due to myelosuppres-
sion from CMV treatment with ganciclovir.
In a retrospective study of 1850 patients admitted
to a medical intensive care unit, 127 (6.9%) showed
microbiological or histopathological evidence of Asper-
gillus [19]. Of these, 89 (70.1%) did not have haemato-
logical malignancies: the most common underlying
medical conditions in these patients were chronic
obstructive pulmonary disease (COPD) in 42%, auto-
immune disorders treated with immunosuppressants in
19%, and solid organ transplants in 10%. Overall
mortality in patients without haematological malig-
nancy was 80%. A. fumigatus is the most commonly
isolated species [20], although other species are
increasingly being encountered. In one study, for
example, the incidence of A. terreus, expressed as a
percentage of all Aspergillus isolates, increased from
1.5% in 1996 to 15.4% in 2001 (PB0.001) [21]. This has
important clinical implications because A. terreus is
resistant to amphotericin B [22,23], and is associated
with rapid disease progression and high mortality; in
one series, six of 11 immunocompromised patients with
invasive pulmonary aspergillosis caused by A. terreus
developed disseminated disease, and 10 died [24].
The incidence of infections caused by zygomycetes is
increasing, as are those of uncommon hyalohyphomy-
coses (caused by Fusarium and Scedosporium spp.)
and phaeohyphomycoses (Bipolaris, Exophiala and
Wangiella spp.). The increase in zygomycosis has been
observed in patients without underlying malignancies
as well as in patients with cancer and those undergoing
bone marrow transplantation [25]. In a review of
929 patients with zygomycosis, patients with diabetes
accounted for the highest proportion of cases (36%),
followed by those without underlying disorders (19%)
and those with malignancies (17%) [25]. Zygomycosis is
highly aggressive and associated with mortality ranging
from 76% in patients with pulmonary infection to 96%
in those with disseminated disease [25]. It has been
discussed that the rising incidence of zygomycosis may
be associated with increasing use of voriconazole to
prevent and treat aspergillosis (Fig. 3) [26,27]; for
example, in a prospective comparison of patients with
IA or zygomycosis, the OR for the development of
zygomycosis associated with voriconazole prophylaxis
was 20.3 (95% CI 3.85108.15, P0.0001) [26].
Diagnosis of systemic fungal infections
Early diagnosis is critical for a favourable outcome
in patients with systemic fungal infections. However,
this remains challenging due to the low sensitivity of
microbiological culture techniques and the low specifi-
city of radiological procedures, particularly in neutro-
penic patients [28,29]. At best, Aspergillus can be isolated
in 34% of sputum specimens and 62% of bronchoalveo-
lar lavage (BAL) specimens from transplant patients
with pulmonary aspergillosis [30,31]. Therefore, histo-
pathological confirmation of the diagnosis is usually
Fig. 3 Increasing incidence of zygomycosis (a) in relation to the use
of voriconazole prophylaxis (b) [26]. BMT, bone marrow transplan-
tation; IA, invasive aspergillosis.
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required, but thrombocytopenia may preclude trans-
bronchial or open lung biopsies [31].
Typical radiographic signs of invasive pulmonary
mould infection include the halo sign and the air
crescent sign. The halo sign is a sensitive but non-
specific marker of IA, and is short-lived: its prevalence
on computed tomography (CT) scans decreases from
68% at 3 days after diagnosis to 22% at 7 days [5]. The
air crescent sign is detected in 8% of cases at 3 days
after diagnosis, in 28% at 7 and 63% at 14 days,
indicating that characteristic CT signs change with
time, and that early and repeated imaging is essential
for diagnosis. Importantly, the presence of a halo sign is
associated with a favourable outcome among those
treated on the basis of this finding. In a subanalysis of a
randomized trial on IA treatment with voriconazole
[6], 61% of patients had halo signs at the time of
presentation, whereas other CT signs, such as consoli-
dations, cavitary lesions and air crescent signs, were
present in 1030% of cases [32]. The response to
treatment was higher in patients with halo signs,
compared with those with other imaging findings
(52% versus 29%, PB0.001), and survival rates at 84
days were also higher (71% versus 53%, PB0.01). In
clinical practice, mould-active AFT is started pre-
emptively in at-risk febrile patients with thoracic CT
findings compatible with early pulmonary filamentous
fungal infection, while microbiological and/or non-
culture based confirmation of mould infection is
sought from blood or respiratory tract specimens (see
below). However, in patients who have been pre-treated
with voriconazole, or who have multiple pulmonary
nodules and pleural effusion on CT scans, zygomycosis
may be more likely than in patients without these
characteristics [26,33].
Diagnostic laboratory testing
Current diagnostic tests for systemic fungal infections
include measurement of Aspergillus galactomannan
(GM) or (1,3)-b-D-glucan, and polymerase chain
reaction (PCR) assays for Aspergillus DNA. GM is a
polysaccharide cell wall component of Aspergillus that
is released into the circulation during fungal growth in
tissues, and can be measured by sensitive enzyme-
linked immunosorbent assay (ELISA) techniques
[3,34,35]. In patients undergoing cancer chemotherapy
or haematopoietic stem cell transplantation, GM
assays have shown a sensitivity of 67100% and a
specificity of 8699% for the detection of Aspergillus,
whereas lower specificities (1530%) have been reported
in non-neutropenic patients [3,34,3640]. When serial
GM testing was performed, a positive GM test
typically preceded the proven diagnosis of IA by
614 days.
(1,3)-b-D-glucan is an integral cell wall component
of a number of pathogenic yeasts and filamentous
fungi [41]. Sensitivities of 67100%, and specificities of
84100%, have been reported with the standard Limu-
lus colorimetric assay [[4144]]. In a recent study, a
positive test for (1,3)-b-D-glucan was found to precede
the diagnosis of IA by a median of 3 days [45].
PCR-based tests for Aspergillus are not yet commer-
cially available and not standardized. They have a high
(9299%) negative predictive value in blood or BAL
samples [34], however, the positive predictive value in
BAL samples is low, apparently due to transient
colonization of the respiratory tract by Aspergillus
[46]. In blood-based assays, sensitivities of 79100%
and specificities of 8193% have been reported [4749].
PCR assays are considerably more sensitive than
culture techniques: in one study, PCR was 19 times
more sensitive than culture for the detection of
A. fumigatus [50].
Treatment and prevention of systemic fungal
infections
Empirical AFT has been demonstrated to prevent
overt invasive fungal infection in the majority high-
risk neutropenic patients with fever refractory to
broad-spectrum antibiotics [5153]. Concerns about
unselected administration of systemic antifungals re-
sulting in significant costs, adverse events, and possible
emergence of resistance to broad-spectrum antifungals
have, however, led to studies on alternative clinical
approaches, restricting AFT to patients with clinical,
imaging and/or laboratory findings more specific for
invasive mould infection than just persisting fever.
Current guidelines on empirical antifungal treatment and
primary treatment of invasive aspergillosis in haematological
patients
Evidence-based guidelines for the empirical adminis-
tration of antifungals in high-risk patients, and for
primary treatment of IA, have been published by the
Infectious Diseases Society of America (IDSA) [54],
and the European Conference on Infections in Leu-
kaemia (ECIL) (Table 1) [55,56]. For empirical therapy,
liposomal amphotericin B (L-AmB) and caspofungin
are supported by the strongest evidence.
In patients with IA, both the ISDA guidelines [54]
and the ECIL-2 guidelines [56] recommend voricona-
zole as first-line therapy [6]. However, the intravenous
form of this agent is not appropriate for all patients, as
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it is subject to numerous drug interactions, mainly due
to inhibition of cytochrome P450 activity [57], and its
use is contraindicated in patients with moderate or
severe renal dysfunction (creatinine clearance B50 ml/
minute). Lipid formulations of amphotericin B (LF-
AB) may be an appropriate alternative to voriconazole
as first-line therapy of IA. In a randomized, double-
blind, trial involving 201 patients with confirmed sys-
temic fungal infections (IA in 97%), the response rates
achieved with liposomal amphotericin B (L-AmB),
3 mg/kg and 10 mg/kg, were 50% and 46%, respectively,
and the 12-week survival rates were 72% and 59%,
respectively [58]. There was no significant difference
in efficacy between the two doses, although nephro-
toxicity and hypokalaemia were significantly more
common with the higher dose. Among 398 patients
who had received amphotericin B lipid complex
(ABLC) for IA, the overall response rate was 65%:
44% were cured or improved, and 21% had stabilization
of infection at the end of therapy (Fig. 4) [20].
In patients not showing a favourable clinical re-
sponse to this first-line therapy, there is a paucity of
data allowing for a clear proof of treatment failure
[59,60]. Switching to second-line or ‘‘salvage’’ AFT
should be considered in patients in whom insufficient
dosing [61], inhibitory drug-drug interactions [62] or
differential diagnoses such as immune reconstitution
syndrome [63] have been properly excluded. There are,
however, few data to guide the choice of second-line
AFT in patients with IA. Both the ECIL-2 and IDSA
guidelines recommend class switches (i.e., LF-AB in
patients primarily treated with voriconazole, voricona-
zole or posaconazole in patients primarily treated with
LF-AB), and combinations with echinocandins such as
caspofungin as an experimental option [54,56]. Among
83 patients with IA (73% of whom had haematological
malignancies or had undergone stem cell or bone
marrow transplantation), who were refractory to or
intolerant of amphotericin B or triazoles, the overall
success rate with caspofungin was 45%; the response
rate was 50% in patients with pulmonary aspergillosis
and 23% in those with disseminated aspergillosis [64].
Salvage therapy with posaconazole resulted in an
overall success rate of 42%, compared with 26%
in historical controls (OR 4.1, 95% CI 1.511.0,
P0.006) [65].
Primary antifungal treatment of zygomycosis
Treatment options in patients with zygomycosis include
LF-AB and posaconazole. The overall response rate in
patients with zygomycosis treated with ABLC was 72%
[66]. Impaired renal function stabilized or improved in
the majority of patients with pre-existing renal disease,
indicating that this formulation is less nephrotoxic than
conventional amphotericin B. In a retrospective review
of 91 patients with zygomycosis treated with posaco-
nazole, the rate of complete plus partial response at 12
weeks was 60%, and a further 21% of patients had
stable disease. [67].
Pre-emptive antifungal therapy
An alternative to empirical AFT, or targeted AFT
restricted to proven invasive mycoses, may be
pre-emptive AFT in high-risk patients with clinical,
laboratory and/or imaging findings indicative for
invasive fungal infection. This approach was evaluated
in 136 high-risk neutropenic patients, all of whom
received prophylaxis with fluconazole and underwent
screening by means of daily GM assays [28]. Seropo-
sitive patients, and those with positive microbiological
tests plus supportive radiological findings, received
L-AmB, 5 mg/kg/day. This approach reduced the use
of AFT in patients with neutropenic fever by 78%, from
35% to 7.7%; furthermore, it led to the early initiation
of AFT in 10 episodes (7.3%) where invasive infection
was not suspected on clinical criteria. These findings
suggest that pre-emptive AFT might provide effective
antifungal control, while reducing exposure to poten-
tially toxic antifungal drugs: however, this approach
has not yet been validated in patients who are on
mould-active antifungal prophylaxis, and in this study
the pre-emptive approach failed to detect non-
Aspergillus infections. A recently published study
Table 1 Recommendations of the 2nd European Conference on
Infections in Leukaemia (ECIL-2) for empirical therapy in patients
with systemic fungal infections [55]
Dose Level of
recommendation*
Liposomal amphotericin B 3 mg/kg A
Caspofungin 50 mg A
Amphotericin B lipid
complex
5 mg/kg B
Amphotericin B colloidal
dispersion
4 mg/kg B
Voriconazole 23 mg/kg i.v. B
Itraconazole 200 mg i.v. B
Amphotericin B
deoxycholate
0.51.0 mg/kg B/D$
Fluconazole 400 mg i.v. C
*Strength of evidence is graded AE. For all agents, both efficacy and
safety are graded I for quality of evidence (i.e., supported by at least
one properly designed, randomized, trial).
$B in the absence of risk factors for renal toxicity (e.g., impaired renal
function at baseline, concomitant nephrotoxic medication, or history
of previous toxicity); D in the presence of such risk factors.
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comparing pre-emptive with empirical AFT in high-
risk, febrile neutropenic patients showed that the
number of proven IMIs increases in patients with
pre-emptive as compared with empirical AFT, but
that overall mortality rates are not significantly
affected, while acquisition costs for antifungals are
reduced [68].
Primary and secondary antifungal prophylaxis
Fluconazole has been standard antifungal prophylaxis
in patients undergoing allogeneic haematopoietic stem
cell transplantation [6973], while itraconazole has not
been shown to provide more effective antifungal
prophylaxis in a direct randomized comparison [74].
Recent studies have shown that posaconazole provides
more effective prophylaxis than these agents in neu-
tropenic patients with acute myeloid leukaemia or
myelodysplastic syndrome [75], and is superior to
fluconazole in patients with severe GVHD [76]. How-
ever, the use of azoles for prophylaxis may preclude
their therapeutic use in patients with established infec-
tions, due to concerns about the emergence of atypical
pathogens and the potential for antifungal resistance
[23,7780]. Current ECIL-2 recommendations for
antifungal prophylaxis are summarized in Table 2
[81]. In patients undergoing repeated episodes of
intensive myelosuppression, preferably those with acute
myeloid leukaemia, bridging systemic AFT from hos-
pital discharge to re-admission by administration of
secondary prophylaxis with a broad-spectrum azole has
been reported to minimize IMI relapses [82,83].
Fig. 4 Clinical response to amphotericin B
lipid complex in 398 patients with IA [20].
Table 2 ECIL-2 recommendations for antifungal prophylaxis [81]
Strength and quality of evidence*
Allogeneic
haematopoietic stem
cell transplantation
Induction
chemotherapy of
acute leukaemia
Fluconazole i.v./oral AI CI
Itraconazole i.v. then oral BI CI
Posaconazole oral AI AI
Micafungin i.v. CI
Candins i.v. Insufficient data
Polyenes i.v. CICII
*Strength of evidence is graded AE; quality of evidence is graded
IIII.
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Systemic mould infections in solid organ
transplant patients
Epidemiology and risk factors
The increasing number of solid organ transplants has
resulted in a concomitant rise in the incidence of
associated systemic fungal infections, such that these
procedures now account for approximately 11% of cases
of IA (Fig. 1) [11]. In patients undergoing liver or lung
transplants, the incidence ranges from 18% and 314%,
respectively, compared with 0.4% for kidney transplant
recipients and 13% for pancreas transplant patients [31].
A mortality rate of 87% is seen in liver transplant patients,
compared with 7080% after other transplants [31].
Infection with Aspergillus can be detected in airway
sample cultures from approximately 2530% of lung
transplant recipients, with IA developing in 315%
[31]. The most common types of infection are tracheo-
bronchitis or bronchial anastomotic infections, which
account for 58% of IA cases; invasive pulmonary
aspergillosis occurs in 32% of cases and disseminated
infection in 22% [31]. The median time to onset of
aspergillosis is 3.2 months after transplantation; 51% of
cases occur within 3 months, and 72% occur within 6
months [31,84]. Risk factors for bronchial anastomotic
infections include airway ischaemia, reperfusion injury,
bilateral lung transplantation, T cell-depleting induc-
tion therapy, and sirolimus-based immunosuppression
[85,86].
Aspergillus infections in patients undergoing liver
transplantation typically occur during the early post-
operative period: median times to onset of 1617 days
have been reported [31,87,88], however, delayed occur-
rences have been documented [89]. Disseminated infec-
tion is more common after liver transplantation than
after other transplants, occurring in 5060% of cases,
compared with 1220% of lung transplant recipients
and 2035% of heart transplant recipients [31].
Renal failure, particularly when renal replacement
therapy is required, is associated with a 1525-fold
increase in the risk of IA [31]. This has important
implications because the number of liver transplants
in patients with renal dysfunction has increased
exponentially since the introduction of MELD (Model
for End-stage Liver Disease) [90]. Re-transplantation is
associated with a 30-fold increase in the risk of IA
[91,92], and accounts for 25% of all IA cases, and 21% of
related deaths, among liver transplant recipients. The
mortality rate was 82% among patients who developed
IA after re-transplantation, compared with 72% among
those developing the infection after their primary
transplant (P0.4) [93]. In the same study, the outcome
of IA was worse after late re-transplantation
(]30 days after primary transplant) than after earlier
re-transplantation. Other risk factors include transplan-
tation for fulminant liver failure, repeated intra-
abdominal or intrathoracic surgery, and preoperative
steroid treatment [31,91,92].
An increasingly high proportion of mould infections
in organ transplant recipients are due to organisms
other than Aspergillus: 27% of all mould infections are
due to other hyaline and dematiaceous moulds and
zygomycetes [94].
Antifungal chemoprophylaxis
Antifungal prophylaxis in liver transplant recipients
has typically involved fluconazole or itraconazole
or, less commonly, LF-AB. A meta-analysis of six
randomized studies comparing these agents with
placebo (five studies) or oral nystatin, showed that
prophylactic treatment reduced the incidence of fungal
colonization (relative risk [RR] 0.45, 95% CI
0.370.55), total proven fungal infections (RR 0.31,
95% CI 0.210.46), and invasive fungal infections (RR
0.33, 95% CI 0.180.59), and decreased mortality
attributable to fungal infections (RR 0.30, 95% CI
0.120.75); however, there was no effect on overall
mortality or the use of empirical treatment for
suspected infections [95]. It should be noted, however,
that the number needed to treat (NNT) to prevent one
case of invasive fungal infection was 5, and to prevent
attributable mortality in one case was 26; indeed, with
regards to side-effects, the NNT actually favoured the
control arm. Moreover, no beneficial effect on invasive
Aspergillus infection was observed.
Several studies have investigated the use of targeted
prophylaxis, mainly with LF-AB, in high-risk liver
transplant patients. In a study in 280 liver transplant
recipients who were treated with ABLC or L-AmB, the
incidences of systemic fungal infections and IA were 6%
and 4%, respectively, compared with 17% (PB0.01) and
10% (P0.08), respectively, in a historical control group
[96]. Among patients with four or more risk factors for
systemic fungal infections, the risk of any systemic fungal
infection was reduced from 36% to 14% (P0.07), and
that of IA from 23% to 5% (P0.08), in patients
receiving the lipid formulations. Moreover, in patients
undergoing renal dialysis, the risk of aspergillosis was
reduced from 32% to 0% (P0.03). In a further study, the
use of ABLC prophylaxis in patients at high or inter-
mediate risk of systemic fungal infection was associated
with a reduction in the incidence of IMI from 5% to 1%
(P0.08), compared with the preintervention period
when antifungal prophylaxis was not provided [97].
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The risk of IA in lung transplant recipients persists
beyond 3 months post-transplant. Antifungal prophy-
laxis during the first 3 months after transplantation
would prevent 62% of tracheobronchitis cases, but
only 36% of pulmonary infections and 50% of
disseminated infections [84]. Long-term antifungal
prophylaxis is therefore necessary in lung transplant
patients. As a result, voriconazole is increasingly the
agent of choice because it can be given orally. In a
retrospective study, the incidence of IA 1 year after
transplantation was 1.5% in patients receiving uni-
versal prophylaxis with voriconazole, compared with
23% (P0.001) in high-risk patients receiving targeted
prophylaxis with itraconazole alone or with aeroso-
lized amphotericin B [98]. However, more patients had
to discontinue treatment because of adverse effects
with voriconazole than with targeted prophylaxis (14%
versus 8%). In 88% of cases, treatment discontinua-
tions are due to elevations of liver enzymes. The use of
aerosolized lipid formulations of amphotericin B may
provide an alternative approach to prophylaxis in lung
transplant recipients, with the potential for improved
tolerability (see below).
Targeted antifungal prophylaxis can significantly
reduce the risk of systemic fungal infections in
high-risk liver transplant recipients. Indeed, the
approach of targeted prophylaxis is becoming widely
adopted: a recent survey of liver transplant centres in
the USA found that 91% were using antifungal
prophylaxis, of whom 72% directed prophylaxis
specifically to high-risk patients [99].
Treatment
For AFT of IA in solid organ transplant patients, the
use of combination therapy with voriconazole and
caspofungin was studied [100]. The survival rate at 90
days was 67.5%, compared with 51% (P0.11) in a
control group receiving an LF-AB. Among patients
with renal failure, mortality was significantly lower in
the combination therapy group than in the control
group (HR 0.32, 95% CI 0.120.85, P0.022). In a
retrospective study of 251 lung transplant recipients, all
three patients receiving combination therapy with
voriconazole and caspofungin survived, compared
with two of 14 patients receiving amphotericin B alone
or with itraconazole (P0.014) [101].
IMIs in paediatric patients
Epidemiology
The incidence of systemic fungal infections in immu-
nocompromised children is increasing, particularly
among children with cancer and those receiving solid
organ or allogeneic haematopoietic stem cell trans-
plants [25,102107]. A review of 666 paediatric cases of
IA found that the children at greatest risk were those
undergoing allogeneic bone marrow transplantation
and those with acute myeloid leukaemia [103].
However, the incidence of IA in these high-risk groups
was approximately 5% only: thus, empirical therapy or
universal prophylaxis creates the risk of over-treatment
in a substantial proportion of patients. The overall
attributable mortality rate associated with systemic
fungal infections in patients up to 20 years of age is
approximately 68% for IA, compared with approxi-
mately 5560% of patients in other age groups [4].
Effective early identification and treatment of high-
risk paediatric patients is therefore essential.
Systemic antifungal treatment
Many antifungal agents have not been studied exten-
sively in paediatric patients. Among 69 children with
IA (median age 7 years) who received voriconazole for
a median of 93 days, the overall response rate was 45%
and a further 7% had stable disease; the highest
response rates were achieved in children with chronic
granulomatous disease, and the lowest in patients
with haematological malignancies [108]. In this study,
however, the voriconazole doses used were those
developed for use in adults, and it is now recognized
that the pharmacokinetics of voriconazole differ mark-
edly in children and adults [109,110]. Higher doses on a
per kilogram basis are required in younger children to
achieve comparable AUCs to adult patients, highlight-
ing the importance of specific paediatric studies and
appropriate dose strategies. It is possible that vorico-
nazole may have greater effectiveness when dosed
appropriately in children. Conversely, increased effec-
tiveness is unknown but increasing toxicity at higher
per kilogram doses is also possible. Further studies with
this agent in children are needed.
In an open-label, compassionate use study in
551 patients with invasive fungal infections, which
included 111 episodes in paediatric patients, the
response rate achieved with ABLC in patients with IA
was 56%, and the overall response rate was 70% [111].
In a further study, involving 46 children (mean age
9.7 years) who received amphotericin B lipid complex
(ABLC) as salvage therapy, response rates in patients
with aspergillosis or candidiasis were 78% and 89%,
respectively [112]. Among 548 paediatric patients (age
520 years) who received ABLC for a median of
15 days (range 1182 days), 300 (54.7%) were transplant
recipients, and most were refractory to or intolerant of
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conventional AFT. Among this subset, 41.7% were
recipients of haematopoietic stem cell transplants,
83.0% of whom from an allogeneic donor. In the
overall transplant group, 71.7% had received one or
more nephrotoxic agents. The overall response rate was
54.9%, and a further 16.9% of patients had a stable
outcome. Among patients with confirmed Aspergillus
or Candida infection, the overall response rates were
59% and 72%, respectively. In the subgroup of patients
with Aspergillus infection, there was no significant
difference in the response rates (complete or partial
response) in transplant and non-transplant patients
(40.5% versus 37.5%, respectively); however, when
patients with stable disease were included, the overall
response rate was significantly higher in the non-
transplant group (71.9% versus 48.6%, P0.05) [113].
In the total patient population, there was no significant
change in serum creatinine during ABLC therapy
although a slight increase was recorded in patients
aged 1220 years, from a median of 1.2 mg/dl at
baseline to 1.5 mg/dl at the end of treatment. These
findings are encouraging for the use of ABLC in
paediatric patients, including high-risk groups such as
transplant recipients.
Aerosolized amphotericin B: a new approach
to antifungal prophylaxis?
Inhaled AFT offers potential advantages, as this
approach delivers the drug directly to the site of
infection while reducing the risk of systemic toxicity
and drug interactions. Amphotericin B has been the
most widely used agent in inhalation therapy, but the
results have been variable [114116]. Nevertheless, a
survey in 2001 revealed that 76% of lung transplant
centres in the USA were using antifungal prophylaxis,
of which 61% were using inhaled amphotericin B [117].
Approximately 75% of the aerosol particles are 18 mm
in diameter, and thus can enter the bronchioles, while
approximately 13% are less than 1 mm in diameter and
can penetrate the alveoli [118].
Clinical studies have investigated the efficacy and
tolerability of aerosolized LF-AB in lung transplant or
stem cell patients, and in patients with haematological
malignancies. An early study, involving 51 lung or
heartlung transplant patients, showed that aerosolized
ABLC was well tolerated in such patients [119]. In a
study in 100 lung transplant recipients receiving aero-
solized amphotericin B deoxycholate (D-AmB), 25 mg,
or aerosolized ABLC, 50 mg, given once daily for
4 days and then once weekly for 7 weeks for prophylaxis
[120], the incidence of systemic fungal infections within
2 months was similar in both groups: 11.8% with
ABLC and 14.3% with D-AmB. However, patients
receiving D-AmB were significantly more likely to
experience adverse events than those receiving ABLC
(OR 2.16, 95% CI 1.104.24, P0.02). The most
common adverse event was worsening dyspnoea, which
occurred in 19.9% of patients receiving D-AmB and
2.1% of ABLC-treated patients, followed by cough
(10.6% versus 2.1%, respectively) and taste distur-
bances (10.6% versus 7.7%). Decreases of 20% or
more in forced expiratory volume in 1 second (FEV1)
or forced vital capacity (FVC) occurred in approxi-
mately 11% of patients in both groups. A further study
in 102 lung transplant patients treated with aerosolized
L-AmB also showed good tolerability [121].
In a study in 382 neutropenic patients with leukae-
mias, non-Hodgkin’s lymphoma or solid tumours, there
was no significant difference in the incidence of IA
between patients who received aerosolized D-AmB or
placebo for antifungal prophylaxis (4% versus 7%,
respectively, P0.37); moreover, there were no signifi-
cant differences in overall mortality or infection-related
mortality between the two groups [116]. More positive
results were obtained in an open-label pilot study
with aerosolized ABLC that included 40 patients
undergoing allogeneic haematopoietic stem cell trans-
plantation [122]. Patients received aerosolized ABLC
once daily for 4 days and then once weekly for 13
weeks, with daily oral fluconazole throughout the
study. Three proven systemic fungal infections occurred
during the study, only one of which developed during
study treatment. There were no cases of aspergillosis;
two cases of C. glabrata fungaemia occurred, which
were attributed to the use of fluconazole prophylaxis.
Aerosolized ABLC was well tolerated: the incidence of
adverse events such as cough, taste disturbances,
nausea or vomiting was 2.2%. Decreases in FEV1 or
FVC of 20% or more occurred after 5.2% of inhaled
treatments. In a further study, involving 271 high-risk
neutropenic patients, treatment with aerosolized L-
AmB significantly reduced the incidence of IA, com-
pared with placebo (4% versus 14%, P0.003) [123].
Aerosolized amphotericin B may provide an effective
and safe alternative to systemic therapy for the
prevention of systemic fungal infections in high-risk
patients. However, large comparative studies are
needed to evaluate the potential benefits of this
approach. [124].
Conclusions
Despite important advances in the diagnosis, treat-
ment, and prevention of systemic fungal infections,
mortality from such infections remains high. The
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potential impact of new treatments, including lipid
formulations of amphotericin B, second-generation
triazoles, and the echinocandins, is reflected in the
inclusion of these agents in current guidelines for
treatment and prophylaxis. New treatment strategies,
such as the use of aerosolized lipid formulations of
amphotericin B, may also have an important role to
play in reducing the burden of mortality associated
with systemic fungal infections. The challenge is to
identify ways of coupling potentially effective treat-
ments with early and reliable identification of patients
at highest risk of infection.
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